STOPDAPT-2 ACS Mortality Prediction Tool

STOPDAPT-2 ACS Mortality Prediction Tool: Explanation and Clinical Context The STOPDAPT-2 ACS trial evaluated an abbreviated dual antiplatelet therapy (DAPT) strategy (1–2 months followed by clopidogrel monotherapy) versus standard 12-month DAPT in patients with acute coronary syndrome undergoing successful percutaneous coronary intervention. Although the primary endpoint did not demonstrate non-inferiority for the abbreviated therapy regarding the composite of cardiovascular death, myocardial infarction, stroke or stent thrombosis, there is growing interest in refined risk stratification for mortality and bleeding in ACS populations. This tool aims to estimate 12-month mortality risk in ACS patients post-PCI by integrating clinical variables (age, renal function, left ventricular ejection fraction, Killip class, ST-segment deviation) that are commonly available early after intervention.

To use: input the required parameters and interpret the output as the approximate probability (%) of death within 12 months. Clinicians should use the result as an adjunct to—but not a substitute for—clinical judgement and guideline-directed therapy.